Diabetic cardiomyopathy: recent evidence from mouse models of type 1 and type 2 diabetes.
about
Diabetic cardiomyopathy-associated dysfunction in spatially distinct mitochondrial subpopulationsThe Role of ERK1/2 in the Development of Diabetic CardiomyopathyPhysiological and structural differences in spatially distinct subpopulations of cardiac mitochondria: influence of cardiac pathologiesEvaluation of the cardiolipin biosynthetic pathway and its interactions in the diabetic heartA mixture of apple pomace and rosemary extract improves fructose consumption-induced insulin resistance in rats: modulation of sarcolemmal CD36 and glucose transporter-4Diagnostic approaches for diabetic cardiomyopathy.Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart.Metabolic and Biochemical Stressors in Diabetic Cardiomyopathy.PET detection of the impact of dobutamine on myocardial glucose metabolism in women with type 1 diabetes mellitus.Cardiac remodeling in obesity.An APPL1-AMPK signaling axis mediates beneficial metabolic effects of adiponectin in the heart.Oxidative stress as a mechanism of added sugar-induced cardiovascular disease.Subcellular trafficking of the substrate transporters GLUT4 and CD36 in cardiomyocytesLeft ventricular dysfunction with reduced functional cardiac reserve in diabetic and non-diabetic LDL-receptor deficient apolipoprotein B100-only miceCardioprotective effects of atrasentan, an endothelin-A receptor antagonist, but not of nitric oxide in diabetic mice with myocyte-specific overexpression of endothelial nitric oxide synthase.Mild Type 2 Diabetes Mellitus Reduces the Susceptibility of the Heart to Ischemia/Reperfusion Injury: Identification of Underlying Gene Expression Changes.Diabetic cardiomyopathy: where are we 40 years later?Influencing factors on cardiac structure and function beyond glycemic control in patients with type 2 diabetes mellitus.Signaling mechanisms of a water soluble curcumin derivative in experimental type 1 diabetes with cardiomyopathy.Aldosterone and the autocrine modulation of potassium currents and oxidative stress in the diabetic rat heart.Mouse models for studies of cardiovascular complications of type 1 diabetes.Alterations in energy metabolism in cardiomyopathies.Mechanisms for increased myocardial fatty acid utilization following short-term high-fat feeding.Neuroendocrine and cardiac metabolic dysfunction and NLRP3 inflammasome activation in adipose tissue and pancreas following chronic spinal cord injury in the mouse.Hyperglycemia Aggravates Hepatic Ischemia Reperfusion Injury by Inducing Chronic Oxidative Stress and Inflammation.Cardiac muscle protein catabolism in diabetes mellitus: activation of the ubiquitin-proteasome system by insulin deficiency.Taking diabetes to heart--deregulation of myocardial lipid metabolism in diabetic cardiomyopathy.Diabetic Cardiomyopathy: An Immunometabolic Perspective.Is there a link between glucose levels and heart failure? An update.Left ventricular pressure-volume measurements and myocardial gene expression profile in type 2 diabetic Goto-Kakizaki rats.Myocardial adipose triglyceride lipase overexpression protects diabetic mice from the development of lipotoxic cardiomyopathy.The cardio-protective signaling and mechanisms of adiponectin.SIRT1 Activation by Resveratrol Alleviates Cardiac Dysfunction via Mitochondrial Regulation in Diabetic Cardiomyopathy Mice.Thioredoxin 2 Offers Protection against Mitochondrial Oxidative Stress in H9c2 Cells and against Myocardial Hypertrophy Induced by Hyperglycemia.Increased expression of the tail-anchored membrane protein SLMAP in adipose tissue from type 2 Tally Ho diabetic mice.Cardiac metabolism in mice: tracer method developments and in vivo application revealing profound metabolic inflexibility in diabetes.Cardiac dysfunction in the diabetic rat: quantitative evaluation using high resolution magnetic resonance imaging.Myocardial metabolism of triacylglycerol-rich lipoproteins in type 2 diabetes.Endothelial dysfunction in Type 2 diabetes correlates with deregulated expression of the tail-anchored membrane protein SLMAP.Metabolism of very-low-density lipoprotein and chylomicrons by streptozotocin-induced diabetic rat heart: effects of diabetes and lipoprotein preference.
P2860
Q23912644-7D9E7CD5-D5F6-499A-9114-AD680E8C9D12Q28075539-0B264E2E-3576-4971-B4E5-3CA84E165498Q28389317-F9D64016-CAD9-4767-B29A-3B63E5AD3BADQ28390032-8665F535-576A-4066-B1A6-BB672016F82FQ28598286-3231314C-D1C6-4E5D-BAF8-6A4752542AA4Q30362092-B37C053E-5884-4081-AEA4-81D82DC36486Q33566045-38768216-D2F8-4AC3-8C6C-34C4F7FA9891Q33740554-B4135400-E5AC-48DA-80B7-17FD444EBB21Q33856448-2295FDF0-06CF-427B-AA65-9020B8D55B25Q34043589-D982260D-5A27-446B-8CC4-22F567F1F487Q34305220-2F431AD7-69D0-4B0B-93AE-7E3A36EE4953Q34452521-E4C6E429-256A-446B-BBA3-4774CE4E63F5Q35100504-5612D845-7F1E-4FAF-81E4-70E31DEAAEABQ35121259-521D8CA9-66B9-44AE-8B1E-7C192E51A68FQ35546217-3C5D74BB-F002-4475-A49C-A3BA0709BB9FQ35851658-ADD120D5-530E-432D-83C6-EF713EE764FAQ36433600-B79EFEBC-5CDA-48A3-8D92-5E3346A93812Q36688287-67E7DB0D-5783-4EB3-A48D-E136E2E9FC71Q36698572-F6DCA92F-A823-4001-98B2-9CC497260DBDQ36736125-673EDC98-F135-4620-ABBB-FBFD509F49BAQ36766171-D02BB552-82A3-47BF-B8D8-65FFC68C30EAQ36970329-C424557A-D7AF-4573-8BA6-E16729C81113Q37176185-88C1553C-AD7B-4883-BE98-DEA49BA70AD1Q37212058-2E4F45E7-AFEE-4180-9361-8CA5951F0329Q37253975-0DAF726F-9B4A-4A35-9275-A95B9F3A7D27Q37325269-E0815E58-C6CB-4B1F-AD22-F3B9138B7504Q37457580-9DEEE3DB-747A-4391-AF29-D232B6B83879Q37741735-FFE3025A-636E-4D77-AC64-CEEAA719D302Q37778757-FDE231C3-9371-478C-A23C-9494FD472002Q39493345-FE4A8FF9-F89E-4483-B015-B3DD29F2DEB8Q40122924-DA615DA4-CB58-4B23-A601-CDA3B23F7B7AQ41106096-621AD739-F6D0-4768-A83D-4908B2C74FD5Q41528591-E4D674D1-900E-4A9A-B114-AF0E5F838472Q41660515-AA2B711E-57A2-4CBD-A760-44B2D5A15A51Q41840285-C7303565-34D1-4EBA-8751-7B93246DC27EQ42487926-6913770E-EE28-4F22-9BAB-B7ED43F02D8CQ42857765-14AF5DE4-DE11-4E1A-8C6E-28A52FA5C530Q46015949-A48843BA-AE46-4DA4-991B-7924CD65C0E5Q46375366-2D328D5A-3283-490F-B663-46152FBF901CQ46379405-BE3FD36A-E402-4FE1-80E0-37B49E6623B5
P2860
Diabetic cardiomyopathy: recent evidence from mouse models of type 1 and type 2 diabetes.
description
2004 nî lūn-bûn
@nan
2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Diabetic cardiomyopathy: recent evidence from mouse models of type 1 and type 2 diabetes.
@ast
Diabetic cardiomyopathy: recent evidence from mouse models of type 1 and type 2 diabetes.
@en
Diabetic cardiomyopathy: recent evidence from mouse models of type 1 and type 2 diabetes.
@nl
type
label
Diabetic cardiomyopathy: recent evidence from mouse models of type 1 and type 2 diabetes.
@ast
Diabetic cardiomyopathy: recent evidence from mouse models of type 1 and type 2 diabetes.
@en
Diabetic cardiomyopathy: recent evidence from mouse models of type 1 and type 2 diabetes.
@nl
prefLabel
Diabetic cardiomyopathy: recent evidence from mouse models of type 1 and type 2 diabetes.
@ast
Diabetic cardiomyopathy: recent evidence from mouse models of type 1 and type 2 diabetes.
@en
Diabetic cardiomyopathy: recent evidence from mouse models of type 1 and type 2 diabetes.
@nl
P2860
P356
P1476
Diabetic cardiomyopathy: recent evidence from mouse models of type 1 and type 2 diabetes.
@en
P2093
David L Severson
P2860
P304
P356
10.1139/Y04-065
P577
2004-10-01T00:00:00Z